variants antibody herceptin interact her2 vegf antigen binding site
interface antibody antigen often depicted lock key suggesting antibody surface can accommodate one antigen describe antibody antigen binding site binds two distinct proteins high affinity isolated variant herceptin therapeutic monoclonal antibody binds human epidermal growth factor receptor her2 basis ability simultaneously interact vascular endothelial growth factor vegf crystallographic mutagenesis studies revealed distinct amino acids antibody called bh1 engage her2 vegf energetically extensive overlap antibody surface areas contacting two antigens affinity-improved version bh1 inhibits her2-and vegf-mediated cell proliferation vitro tumor progression mouse models two-in-one antibodies challenge monoclonal antibody paradigm one binding site one antigen also provide new opportunities antibody-based therapy
